Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H16N2O5 |
Molecular Weight | 256.2551 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O
InChI
InChIKey=XACKNLSZYYIACO-DJLDLDEBSA-N
InChI=1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)/t7-,8+,9+/m0/s1
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
5-Propyl-2'-deoxyuridine: a specific anti-herpes agent. | 1978 Mar |
|
Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice. | 1979 Nov |
|
5-substituted deoxyuridines--structural requirements for antiviral activity against herpes simplex virus types 1 and 2 and possible biochemical basis for relative potency. | 1984 Jun |
|
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters. | 1986 Apr |
|
Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine. | 1986 Jan |
|
Incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells. | 1988 Dec 1 |
|
Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans. | 2003 Aug 4 |
|
Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors. | 2003 May-Aug |
|
Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. | 2003 Sep 15 |
|
3D-QSAR studies on antitubercular thymidine monophosphate kinase inhibitors based on different alignment methods. | 2006 Feb 15 |
|
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus. | 2010 Nov 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1894930
topical edoxudine 3.0% cream
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD06BB09
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
||
|
WHO-ATC |
D06BB09
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
||
|
NCI_THESAURUS |
C29575
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
15176-29-1
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
100000080512
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL318153
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
SUB06460MIG
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
m4833
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
66377
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
758405
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
DTXSID4045890
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
49428
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
C87662
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
15ZQM81Y3R
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
C022811
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
239-226-1
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
DB13421
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
5512
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
3173
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
EDOXUDINE
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY | |||
|
U-62
Created by
admin on Fri Dec 15 15:23:19 GMT 2023 , Edited by admin on Fri Dec 15 15:23:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY